Yin Feng, Yang Chengbin, Wang Qianqian, Zeng Shuwen, Hu Rui, Lin Guimiao, Tian Jinglin, Hu Siyi, Lan Rong Feng, Yoon Ho Sup, Lu Fei, Wang Kuan, Yong Ken-Tye
1. School of Electrical and Electronic Engineering, Nanyang Technological University, Singapore 639798, Singapore.
3. Laboratory of Chemical Genetics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 518055, China.
Theranostics. 2015 Apr 20;5(8):818-33. doi: 10.7150/thno.11335. eCollection 2015.
In this work, we report the engineering of polyelectrolyte polymers coated Gold nanorods (AuNRs)-based nanocarriers that are capable of co-delivering small interfering RNA (siRNA) and an anticancer drug doxorubicin (DOX) to Panc-1 cancer cells for combination of both chemo- and siRNA-mediated mutant K-Ras gene silencing therapy. Superior anticancer efficacy was observed through synergistic combination of promoted siRNA and DOX release upon irradiating the nanoplex formulation with 665 nm light. Our antitumor study shows that the synergistic effect of AuNRs nanoplex formulation with 665 nm light treatment is able to inhibit the in vivo tumor volume growth rate by 90%. The antitumor effect is contributed from the inactivation of K-Ras gene and thereby causing a profound synthesis (S) phase arrest in treated Panc-1 cells. Our study shows that the percentage of Panc-1 cells treated by nanoplex formulation with S phase is determined to be 35% and it is 17% much higher than that of Panc-1 cells without any treatments. The developed nanotherapy formulation here, that combines chemotherapy, RNA silencing and NIR window light-mediated therapy, will be seen to be the next natural step to be taken in the clinical research for improving the therapeutic outcomes of the pancreatic adenocarcinoma treatment.
在本研究中,我们报道了基于聚电解质聚合物包覆金纳米棒(AuNRs)的纳米载体的工程化,该纳米载体能够将小干扰RNA(siRNA)和抗癌药物阿霉素(DOX)共同递送至Panc-1癌细胞,以实现化学疗法和siRNA介导的突变K-Ras基因沉默疗法的联合应用。在用665 nm光照射纳米复合物制剂后,通过促进siRNA和DOX释放的协同组合,观察到了卓越的抗癌效果。我们的抗肿瘤研究表明,AuNRs纳米复合物制剂与665 nm光处理的协同效应能够将体内肿瘤体积生长速率抑制90%。这种抗肿瘤效应源于K-Ras基因的失活,从而导致经处理的Panc-1细胞出现深度合成(S)期阻滞。我们的研究表明,纳米复合物制剂处理的处于S期的Panc-1细胞百分比确定为35%,比未进行任何处理的Panc-1细胞高17%。这里开发的纳米治疗制剂结合了化学疗法、RNA沉默和近红外窗口光介导疗法,将被视为在临床研究中为改善胰腺腺癌治疗效果而采取的下一个自然步骤。